Table 2.
Comparison of IL-6, TRX1, and MIF plasma levels, as well as APACHE II, SAPS II, and SOFA scores in survivors and nonsurvivors in the septic group at baseline and at 24 and 48 hours.
| Survivor (n = 8) | Nonsurvivor (n = 7) | P-value | ||
|---|---|---|---|---|
| IL-6 (pg/ml) | t0 | 578.7; 451.4–579.9 | 576.1; 521.9–581.6 | >.05 |
| t24 | 262.2; 103.4–300.3 | 371.2; 153.6–553.7 | >.05 | |
| t48 | 53.0; 41.0–79.6 | 51.7; 47.4–312.0 | >.05 | |
| P-value | t0-t24-t48 | >.05 | >.05 | |
|
| ||||
| TRX1 (ng/ml) | t0 | 26.8; 14.2–44.7 | 57.5; 22.0–82.2 | >.05 |
| t24 | 25.8; 13.4–47.8 | 22.9; 16.3–28.0 | >.05 | |
| t48 | 12.9; 9.5–16.1 | 23.8; 21.1–27.9 | >.05 | |
| P-value | t0-t24-t48 | >.05 | >.05 | |
|
| ||||
| MIF (pg/ml) | t0 | 1645.8; 345.1–4078.7 | 1821.1; 971.9–3147.6 | >.05 |
| t24 | 624.7; 396.3–1899.5 | 889.0; 432.4–1467.3 | >.05 | |
| t48 | 421.8; 315.3–692.7 | 951.1; 425.8–1469.0 | >.05 | |
| P-value | t0-t24-t48 | >.05 | .05* | |
|
| ||||
| APACHE II (points) | t0 | 43.0; 35.0–45.0 | 33.0; 32.5–37.0 | >.05 |
| t24 | 35.0; 29.5–40.8 | 43.0; 38.8–45.0 | >.05 | |
| t48 | 34.0; 23.5–38.5 | 35.0; 35.0–36.0 | >.05 | |
| P-value | t0-t24-t48 | >.05 | >.05 | |
|
| ||||
| SOFA (points) | t0 | 13.0; 11.0–15.0 | 16.5; 15.0–18.0 | >.05 |
| t24 | 13.0: 11.5–15.5 | 16.5; 14.3–18.0 | >.05 | |
| t48 | 14.0: 12.0–15.0 | 18.0; 9.0–18.0 | >.05 | |
| P-value | t0-t24-t48 | >.05 | >.05 | |
|
| ||||
| SAPS II (points) | t0 | 60.5; 54.8–66.3 | 81.0; 72.3–89.3 | >.05 |
| t24 | 73.0; 60.0–77.0 | 76.5; 66.0–84.5 | >.05 | |
| t48 | 63.0; 57.5–75.5 | 76.0; 71.0–90.0 | >.05 | |
| P-value | t0-t24-t48 | >.05 | >.05 | |
Data are presented by median and interquartile range (Q1–Q3).